KineMed Inc. announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (PFE: Quote) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes.
KineMed stated that the collaboration employs its novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
"This platform has been useful in accelerating advancement and de-risking compounds in Type II diabetes. We look forward to continuing our work with Pfizer on their compounds in preclinical and clinical trials," said Marc Hellerstein, President, Chief Science Officer and Co-founder at KineMed.
by RTT Staff Writer
For comments and feedback: email@example.com